Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …

Non-Hodgins's lymphoma (NHL) is the most common hematological malignancy worldwide,
accounting for nearly 3% of cancer diagnoses and deaths. NHL is the seventh most …

Collectively, lymphoid neoplasms are the fourth most common cancer and the sixth leading
cause of cancer death in the United States. The authors provide contemporary lymphoid …

Abstract Background Non-Hodgkin lymphoma (NHL) comprises biologically and clinically
heterogeneous subtypes. Previously, study size has limited the ability to compare and …

Our understanding of familial predisposition to lymphoma (collectively defined as non-
Hodgkin lymphoma [NHL], Hodgkin lymphoma [HL], and chronic lymphocytic leukemia …

Diffuse large B-cell lymphoma (DLBCL) represents a curable disease with a 60–70%
chance of cure with current R-CHOP chemoimmunotherapy. However, 30–40% of patients …

Non-Hodgkin lymphoma (NHL) consists of many histologically and biologically distinct
lymphoid malignancies with poorly understood, but possibly distinct, etiologies. The patterns …

As the most common non-Hodgkin lymphoma subtype, diffuse large B-cell lymphoma
(DLBCL) incidence patterns generally parallel that for NHL overall. Globally, DLBCL …

Non-Hodgkin lymphoma (NHL) comprises numerous biologically and clinically
heterogeneous subtypes, with limited data examining the risk factors for these distinct …

Lymphoma is a name for malignant diseases of the lymphatic system including Hodgkin's
lymphoma and non‐Hodgkin's lymphoma. Although several approaches are used for the …